Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - 30 Jan 2025 Form 4 Insider Report for Metsera, Inc. (MTSR)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter N. McIsaac, Authorized Person
Issuer symbol
MTSR
Transactions as of
30 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Feb 2025, 18:48:52 UTC
Previous filing
15 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MTSR Common Stock Conversion of derivative security +1,857,699 1,857,699 30 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTSR Series B Preferred Stock Conversion of derivative security $0 -4,365,079 -100% $0.000000 0 30 Jan 2025 Common Stock 1,857,699 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.